Table 3.

Analysis of correlation factors with PFS and OS.

Characteristics	PFS						OS
	Univariate analysis			Multivariate analysis			Univariate analysis			Multivariate analysis
	HR	95% CI	P Value	HR	95% CI	P Value	HR	95% CI	P Value	HR	95% CI	P Value
NLR	1.033	0.944 to 1.131	0.481				1.160	1.073 to 1.253	0.0001	1.057	0.887 to 1.259	0.534
PLR	1.001	0.999 to 1.003	0.229				1.001	1.000 to 1.003	0.119
NAC	1.187	0.611 to 2.307	0.614				0.955	0.422 to 2.158	0.911
Histology	1.745	0.629 to 4.841	0.284				1.119	0.399 to 3.136	0.831
Stage disease of first diagnosis	0.837	0.517 to 1.356	0.469				1.206	0.748 to 1.944	0.443
Ki67	1.008	0.997 to 1.019	0.160				0.997	0.986 to 1.007	0.550
Subtype	1.365	0.798 to 2.335	0.256				1.859	1.004 to 3.440	0.048	1.916	0.889 to 4.132	0.097
Interval between initial recurrence	0.996	0.989 to 1.003	0.273				0.999	0.992 to 1.006	0.770
Site of primary recurrence	1.208	0.590 to 2.475	0.605				0.726	0.348 to 1.513	0.392
Number of organs in primary recurrence	0.823	0.479 to 1.415	0.481				0.521	0.287 to 0.948	0.033	0.962	0.389 to 2.379	0.933
Number of organs before apatinib	0.862	0.501 to 1.482	0.591				0.547	0.301 to 0.995	0.048	0.658	0.229 to 1.892	0.437
First-line rescue effect	1.103	0.653 to 1.864	0.714				1.032	0.559 to 1.904	0.919
Number of prior chemotherapy regimens	2.265	1.262 to 4.064	0.006	1.971	1.077 to 3.607	0.028	5.525	2.425 to 12.585	0.0001	4.555	1.718 to 12.080	0.002
Brain Metastasis	2.090	1.016 to 4.299	0.045	1.731	0.833 to 3.596	0.142	1.793	0.879 to 3.657	0.109
Lung Metastasis	1.151	0.660 to 2.008	0.620				0.812	0.443 to 1.490	0.501
Liver Metastasis	0.750	0.422 to 1.334	0.328				1.431	0.780 to 2.625	0.247
Apatinib dose	1.012	0.581 to 1.764	0.966				0.607	0.306 to 1.202	0.152
Apatinib monotherapy	0.725	0.422 to 1.243	0.242				0.721	0.407 to 1.279	0.264
United capecitabine	0.922	0.666 to 1.276	0.625				0.964	0.676 to 1.375	0.841